Home Healthcare Biotechnology Live Attenuated Vaccines Market

Live Attenuated Vaccines Market Size, Share & Trends Analysis Report By Product (Viral, Bacterial), By Disease Indication (Measles, Mumps, and Rubella (MMR), Varicella (Chickenpox), Influenza, Rotavirus, Yellow Fever, Polio, Others), By Route of Administration (Oral, Parenteral, Intranasal), By Age Group (Pediatric, Adult) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: May 25, 2026 | Author: Debashree B | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Live Attenuated Vaccines Market, By Product 2022-2034 (USD MILLION/ Units)
    1. Viral
    2. Bacterial
  2. Live Attenuated Vaccines Market, By Disease Indication 2022-2034 (USD MILLION/ Units)
    1. Measles, Mumps, and Rubella (MMR)
    2. Varicella (Chickenpox)
    3. Influenza
    4. Rotavirus
    5. Yellow Fever
    6. Polio
    7. Others
  3. Live Attenuated Vaccines Market, By Route of Administration 2022-2034 (USD MILLION/ Units)
    1. Oral
    2. Parenteral
    3. Intranasal
  4. Live Attenuated Vaccines Market, By Age Group 2022-2034 (USD MILLION/ Units)
    1. Pediatric
    2. Adult
  5. Regional Live Attenuated Vaccines Market
    1. North America
      1. North America Live Attenuated Vaccines Market By Product 2022-2034 (USD MILLION/ Units)
        1. Viral
        2. Bacterial
      2. North America Live Attenuated Vaccines Market By Disease Indication 2022-2034 (USD MILLION/ Units)
        1. Measles, Mumps, and Rubella (MMR)
        2. Varicella (Chickenpox)
        3. Influenza
        4. Rotavirus
        5. Yellow Fever
        6. Polio
        7. Others
      3. North America Live Attenuated Vaccines Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Parenteral
        3. Intranasal
      4. North America Live Attenuated Vaccines Market By Age Group 2022-2034 (USD MILLION/ Units)
        1. Pediatric
        2. Adult
      5. U.S.
        1. Viral
        2. Bacterial
        3. Measles, Mumps, and Rubella (MMR)
        4. Varicella (Chickenpox)
        5. Influenza
        6. Rotavirus
        7. Yellow Fever
        8. Polio
        9. Others
        10. Oral
        11. Parenteral
        12. Intranasal
        13. Pediatric
        14. Adult
      6. Canada
        1. Viral
        2. Bacterial
        3. Measles, Mumps, and Rubella (MMR)
        4. Varicella (Chickenpox)
        5. Influenza
        6. Rotavirus
        7. Yellow Fever
        8. Polio
        9. Others
        10. Oral
        11. Parenteral
        12. Intranasal
        13. Pediatric
        14. Adult
    2. Europe
      1. Europe Live Attenuated Vaccines Market By Product 2022-2034 (USD MILLION/ Units)
        1. Viral
        2. Bacterial
      2. Europe Live Attenuated Vaccines Market By Disease Indication 2022-2034 (USD MILLION/ Units)
        1. Measles, Mumps, and Rubella (MMR)
        2. Varicella (Chickenpox)
        3. Influenza
        4. Rotavirus
        5. Yellow Fever
        6. Polio
        7. Others
      3. Europe Live Attenuated Vaccines Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Parenteral
        3. Intranasal
      4. Europe Live Attenuated Vaccines Market By Age Group 2022-2034 (USD MILLION/ Units)
        1. Pediatric
        2. Adult
      5. U.K.
        1. Viral
        2. Bacterial
        3. Measles, Mumps, and Rubella (MMR)
        4. Varicella (Chickenpox)
        5. Influenza
        6. Rotavirus
        7. Yellow Fever
        8. Polio
        9. Others
        10. Oral
        11. Parenteral
        12. Intranasal
        13. Pediatric
        14. Adult
      6. Germany
        1. Viral
        2. Bacterial
        3. Measles, Mumps, and Rubella (MMR)
        4. Varicella (Chickenpox)
        5. Influenza
        6. Rotavirus
        7. Yellow Fever
        8. Polio
        9. Others
        10. Oral
        11. Parenteral
        12. Intranasal
        13. Pediatric
        14. Adult
      7. France
        1. Viral
        2. Bacterial
        3. Measles, Mumps, and Rubella (MMR)
        4. Varicella (Chickenpox)
        5. Influenza
        6. Rotavirus
        7. Yellow Fever
        8. Polio
        9. Others
        10. Oral
        11. Parenteral
        12. Intranasal
        13. Pediatric
        14. Adult
      8. Spain
        1. Viral
        2. Bacterial
        3. Measles, Mumps, and Rubella (MMR)
        4. Varicella (Chickenpox)
        5. Influenza
        6. Rotavirus
        7. Yellow Fever
        8. Polio
        9. Others
        10. Oral
        11. Parenteral
        12. Intranasal
        13. Pediatric
        14. Adult
      9. Italy
        1. Viral
        2. Bacterial
        3. Measles, Mumps, and Rubella (MMR)
        4. Varicella (Chickenpox)
        5. Influenza
        6. Rotavirus
        7. Yellow Fever
        8. Polio
        9. Others
        10. Oral
        11. Parenteral
        12. Intranasal
        13. Pediatric
        14. Adult
      10. Russia
        1. Viral
        2. Bacterial
        3. Measles, Mumps, and Rubella (MMR)
        4. Varicella (Chickenpox)
        5. Influenza
        6. Rotavirus
        7. Yellow Fever
        8. Polio
        9. Others
        10. Oral
        11. Parenteral
        12. Intranasal
        13. Pediatric
        14. Adult
      11. Nordic
        1. Viral
        2. Bacterial
        3. Measles, Mumps, and Rubella (MMR)
        4. Varicella (Chickenpox)
        5. Influenza
        6. Rotavirus
        7. Yellow Fever
        8. Polio
        9. Others
        10. Oral
        11. Parenteral
        12. Intranasal
        13. Pediatric
        14. Adult
      12. Benelux
        1. Viral
        2. Bacterial
        3. Measles, Mumps, and Rubella (MMR)
        4. Varicella (Chickenpox)
        5. Influenza
        6. Rotavirus
        7. Yellow Fever
        8. Polio
        9. Others
        10. Oral
        11. Parenteral
        12. Intranasal
        13. Pediatric
        14. Adult
      13. Rest of Europe
        1. Viral
        2. Bacterial
        3. Measles, Mumps, and Rubella (MMR)
        4. Varicella (Chickenpox)
        5. Influenza
        6. Rotavirus
        7. Yellow Fever
        8. Polio
        9. Others
        10. Oral
        11. Parenteral
        12. Intranasal
        13. Pediatric
        14. Adult
    3. APAC
      1. APAC Live Attenuated Vaccines Market By Product 2022-2034 (USD MILLION/ Units)
        1. Viral
        2. Bacterial
      2. APAC Live Attenuated Vaccines Market By Disease Indication 2022-2034 (USD MILLION/ Units)
        1. Measles, Mumps, and Rubella (MMR)
        2. Varicella (Chickenpox)
        3. Influenza
        4. Rotavirus
        5. Yellow Fever
        6. Polio
        7. Others
      3. APAC Live Attenuated Vaccines Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Parenteral
        3. Intranasal
      4. APAC Live Attenuated Vaccines Market By Age Group 2022-2034 (USD MILLION/ Units)
        1. Pediatric
        2. Adult
      5. China
        1. Viral
        2. Bacterial
        3. Measles, Mumps, and Rubella (MMR)
        4. Varicella (Chickenpox)
        5. Influenza
        6. Rotavirus
        7. Yellow Fever
        8. Polio
        9. Others
        10. Oral
        11. Parenteral
        12. Intranasal
        13. Pediatric
        14. Adult
      6. Korea
        1. Viral
        2. Bacterial
        3. Measles, Mumps, and Rubella (MMR)
        4. Varicella (Chickenpox)
        5. Influenza
        6. Rotavirus
        7. Yellow Fever
        8. Polio
        9. Others
        10. Oral
        11. Parenteral
        12. Intranasal
        13. Pediatric
        14. Adult
      7. Japan
        1. Viral
        2. Bacterial
        3. Measles, Mumps, and Rubella (MMR)
        4. Varicella (Chickenpox)
        5. Influenza
        6. Rotavirus
        7. Yellow Fever
        8. Polio
        9. Others
        10. Oral
        11. Parenteral
        12. Intranasal
        13. Pediatric
        14. Adult
      8. India
        1. Viral
        2. Bacterial
        3. Measles, Mumps, and Rubella (MMR)
        4. Varicella (Chickenpox)
        5. Influenza
        6. Rotavirus
        7. Yellow Fever
        8. Polio
        9. Others
        10. Oral
        11. Parenteral
        12. Intranasal
        13. Pediatric
        14. Adult
      9. Australia
        1. Viral
        2. Bacterial
        3. Measles, Mumps, and Rubella (MMR)
        4. Varicella (Chickenpox)
        5. Influenza
        6. Rotavirus
        7. Yellow Fever
        8. Polio
        9. Others
        10. Oral
        11. Parenteral
        12. Intranasal
        13. Pediatric
        14. Adult
      10. Singapore
        1. Viral
        2. Bacterial
        3. Measles, Mumps, and Rubella (MMR)
        4. Varicella (Chickenpox)
        5. Influenza
        6. Rotavirus
        7. Yellow Fever
        8. Polio
        9. Others
        10. Oral
        11. Parenteral
        12. Intranasal
        13. Pediatric
        14. Adult
      11. Taiwan
        1. Viral
        2. Bacterial
        3. Measles, Mumps, and Rubella (MMR)
        4. Varicella (Chickenpox)
        5. Influenza
        6. Rotavirus
        7. Yellow Fever
        8. Polio
        9. Others
        10. Oral
        11. Parenteral
        12. Intranasal
        13. Pediatric
        14. Adult
      12. South East Asia
        1. Viral
        2. Bacterial
        3. Measles, Mumps, and Rubella (MMR)
        4. Varicella (Chickenpox)
        5. Influenza
        6. Rotavirus
        7. Yellow Fever
        8. Polio
        9. Others
        10. Oral
        11. Parenteral
        12. Intranasal
        13. Pediatric
        14. Adult
      13. Rest of Asia-Pacific
        1. Viral
        2. Bacterial
        3. Measles, Mumps, and Rubella (MMR)
        4. Varicella (Chickenpox)
        5. Influenza
        6. Rotavirus
        7. Yellow Fever
        8. Polio
        9. Others
        10. Oral
        11. Parenteral
        12. Intranasal
        13. Pediatric
        14. Adult
    4. Middle East and Africa
      1. Middle East and Africa Live Attenuated Vaccines Market By Product 2022-2034 (USD MILLION/ Units)
        1. Viral
        2. Bacterial
      2. Middle East and Africa Live Attenuated Vaccines Market By Disease Indication 2022-2034 (USD MILLION/ Units)
        1. Measles, Mumps, and Rubella (MMR)
        2. Varicella (Chickenpox)
        3. Influenza
        4. Rotavirus
        5. Yellow Fever
        6. Polio
        7. Others
      3. Middle East and Africa Live Attenuated Vaccines Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Parenteral
        3. Intranasal
      4. Middle East and Africa Live Attenuated Vaccines Market By Age Group 2022-2034 (USD MILLION/ Units)
        1. Pediatric
        2. Adult
      5. UAE
        1. Viral
        2. Bacterial
        3. Measles, Mumps, and Rubella (MMR)
        4. Varicella (Chickenpox)
        5. Influenza
        6. Rotavirus
        7. Yellow Fever
        8. Polio
        9. Others
        10. Oral
        11. Parenteral
        12. Intranasal
        13. Pediatric
        14. Adult
      6. Turkey
        1. Viral
        2. Bacterial
        3. Measles, Mumps, and Rubella (MMR)
        4. Varicella (Chickenpox)
        5. Influenza
        6. Rotavirus
        7. Yellow Fever
        8. Polio
        9. Others
        10. Oral
        11. Parenteral
        12. Intranasal
        13. Pediatric
        14. Adult
      7. Saudi Arabia
        1. Viral
        2. Bacterial
        3. Measles, Mumps, and Rubella (MMR)
        4. Varicella (Chickenpox)
        5. Influenza
        6. Rotavirus
        7. Yellow Fever
        8. Polio
        9. Others
        10. Oral
        11. Parenteral
        12. Intranasal
        13. Pediatric
        14. Adult
      8. South Africa
        1. Viral
        2. Bacterial
        3. Measles, Mumps, and Rubella (MMR)
        4. Varicella (Chickenpox)
        5. Influenza
        6. Rotavirus
        7. Yellow Fever
        8. Polio
        9. Others
        10. Oral
        11. Parenteral
        12. Intranasal
        13. Pediatric
        14. Adult
      9. Egypt
        1. Viral
        2. Bacterial
        3. Measles, Mumps, and Rubella (MMR)
        4. Varicella (Chickenpox)
        5. Influenza
        6. Rotavirus
        7. Yellow Fever
        8. Polio
        9. Others
        10. Oral
        11. Parenteral
        12. Intranasal
        13. Pediatric
        14. Adult
      10. Nigeria
        1. Viral
        2. Bacterial
        3. Measles, Mumps, and Rubella (MMR)
        4. Varicella (Chickenpox)
        5. Influenza
        6. Rotavirus
        7. Yellow Fever
        8. Polio
        9. Others
        10. Oral
        11. Parenteral
        12. Intranasal
        13. Pediatric
        14. Adult
      11. Rest of MEA
        1. Viral
        2. Bacterial
        3. Measles, Mumps, and Rubella (MMR)
        4. Varicella (Chickenpox)
        5. Influenza
        6. Rotavirus
        7. Yellow Fever
        8. Polio
        9. Others
        10. Oral
        11. Parenteral
        12. Intranasal
        13. Pediatric
        14. Adult
    5. LATAM
      1. LATAM Live Attenuated Vaccines Market By Product 2022-2034 (USD MILLION/ Units)
        1. Viral
        2. Bacterial
      2. LATAM Live Attenuated Vaccines Market By Disease Indication 2022-2034 (USD MILLION/ Units)
        1. Measles, Mumps, and Rubella (MMR)
        2. Varicella (Chickenpox)
        3. Influenza
        4. Rotavirus
        5. Yellow Fever
        6. Polio
        7. Others
      3. LATAM Live Attenuated Vaccines Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Parenteral
        3. Intranasal
      4. LATAM Live Attenuated Vaccines Market By Age Group 2022-2034 (USD MILLION/ Units)
        1. Pediatric
        2. Adult
      5. Brazil
        1. Viral
        2. Bacterial
        3. Measles, Mumps, and Rubella (MMR)
        4. Varicella (Chickenpox)
        5. Influenza
        6. Rotavirus
        7. Yellow Fever
        8. Polio
        9. Others
        10. Oral
        11. Parenteral
        12. Intranasal
        13. Pediatric
        14. Adult
      6. Mexico
        1. Viral
        2. Bacterial
        3. Measles, Mumps, and Rubella (MMR)
        4. Varicella (Chickenpox)
        5. Influenza
        6. Rotavirus
        7. Yellow Fever
        8. Polio
        9. Others
        10. Oral
        11. Parenteral
        12. Intranasal
        13. Pediatric
        14. Adult
      7. Argentina
        1. Viral
        2. Bacterial
        3. Measles, Mumps, and Rubella (MMR)
        4. Varicella (Chickenpox)
        5. Influenza
        6. Rotavirus
        7. Yellow Fever
        8. Polio
        9. Others
        10. Oral
        11. Parenteral
        12. Intranasal
        13. Pediatric
        14. Adult
      8. Chile
        1. Viral
        2. Bacterial
        3. Measles, Mumps, and Rubella (MMR)
        4. Varicella (Chickenpox)
        5. Influenza
        6. Rotavirus
        7. Yellow Fever
        8. Polio
        9. Others
        10. Oral
        11. Parenteral
        12. Intranasal
        13. Pediatric
        14. Adult
      9. Colombia
        1. Viral
        2. Bacterial
        3. Measles, Mumps, and Rubella (MMR)
        4. Varicella (Chickenpox)
        5. Influenza
        6. Rotavirus
        7. Yellow Fever
        8. Polio
        9. Others
        10. Oral
        11. Parenteral
        12. Intranasal
        13. Pediatric
        14. Adult
      10. Rest of LATAM
        1. Viral
        2. Bacterial
        3. Measles, Mumps, and Rubella (MMR)
        4. Varicella (Chickenpox)
        5. Influenza
        6. Rotavirus
        7. Yellow Fever
        8. Polio
        9. Others
        10. Oral
        11. Parenteral
        12. Intranasal
        13. Pediatric
        14. Adult
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.